NASDAQ · Biotechnology

BNBX (BNBX) Stock

$0.16 +0.00% NASDAQ: BNBX Healthcare

Valuation

MetricValue
Price$0.16
Market Cap$210492
P/E Ratio0.00
P/B Ratio0.25
P/S Ratio0.24
EPS (TTM)$0.00
52-Week High$7.15
52-Week Low$0.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-750.00%
ROA-375.00%
ROCE-800.00%
Gross Margin-800.00%
Operating Margin-800.00%
Net Margin-16.47%
Debt/Equity0.00
Current Ratio1.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$9.0M$18.0M$13.0M$3.0M$2.0M
Operating Profit$-13.0M$-14.0M$-11.0M$-14.0M$-16.0M
Net Profit$-14.0M$-8.0M$-10.0M$-7.0M$-15.0M
EPS$-28630.14$-9741.86$-570.37$-68.25$-134.23
Op Margin-147.9%-76.9%-81.9%-408.7%-750.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$14.0M$22.0M$14.0M$13.0M$4.0M
Total Liabilities$3.0M$9.0M$9.0M$4.0M$2.0M
Cash$7.0M$15.0M$7.0M$6.0M$2.0M
Borrowings$0$0$1.0M$1.0M$0

Latest News

BNB Plus Receives Nasdaq Delisting Determination and Moves Trading to OTCQB Market InvestorsHub · Jul 13, 2026 BNB Plus Receives Nasdaq Delisting Notice, Plans OTC Listing MT Newswires · Jul 13, 2026 BNB Plus Adds $4.1M as Crypto Treasury Reset Moves Forward CryptoProwl · May 26, 2026 BNB Plus: Fiscal Q2 Earnings Snapshot Associated Press · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow————$-13.0M
Investing Cash Flow————$-1.0M
Financing Cash Flow————$0
Net Cash Flow————$-5.0M
Free Cash Flow$0$0$0$0$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-2792.88%
Quick Ratio1.74
Interest Coverage—
Return 1Y-97.52%
Return 3Y-100.00%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BGMS $0.91 +3.73% 0.17 $1.99M 0.00%
BNGO $1.07 +0.94% -1.16 $12.28M 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
ISPC $2.03 +1.00% -0.64 $281890 0.00%
KZIAKazia Therapeutics Ltd ADR $14.54 +2.76% -2.01 $23.55M 0.00%

About BNBX

BNBX is led by CEO Clay D. Shorrock, employs 46 people, headquartered in US, publicly traded since 2025.

BNBX stock trades at $0.16 with a market capitalization of $210492. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.25, price-to-sales of 0.24. Over the past 52 weeks the stock has ranged between $0.16 and $7.15, and currently trades 97.8% below its 52-week high.

On profitability, BNBX generates a return on equity (ROE) of -750.00%, return on capital employed of -800.00%, an operating margin of -800.00%, a net profit margin of -16.47%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides